Previously 14–3-3 proteins have been implicated in interactions with several proteins associated with PD including α-synuclein, Parkin and LRRK2 [35] and targeting 14–3-3 PPI using small molecules offers a promising strategy for PD and other neurodegenerative diseases [36]. This evidence concerns the gene PRKN and Parkinson disease.